Ep2 Receptor Agonists
A compound selected from one of the following: or a salt, solvate, chemically protected form or prodrug thereof, and its use in treating conditions alleviated by agonism of an EP 2 receptor.
1 . A compound selected from one of the following:
or a salt, solvate, chemically protected form or prodrug thereof.
2 . (trans-2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 90% by weight is selected from one of the following forms:
or a salt, solvate, chemically protected form or prodrug thereof.
3 . 2-[4-(1-hydroxyhexyl)phenyl]-5-oxo-cyclopentaneheptanoic acid, of which at least 80% by weight is in one of the following forms:
or a salt, solvate, chemically protected form or prodrug thereof.
4 . A method of making a compound according to claim 1 .
5 . A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, for use in a method of therapy.
6 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.
7 . The use of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a condition alleviated by agonism of an EP 2 receptor.
8 . The use according to claim 7 , wherein the condition alleviated by agonism of an EP 2 receptor is selected from the group consisting of: glaucoma, dysmenorrhoea and pre-term labour.
9 . A method of treating a condition which can be alleviated by agonism of an EP 2 receptor, which method comprises administering to a patient in need of treatment an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
10 . The method according to claim 9 , wherein the condition alleviated by agonism of an EP 2 receptor is selected from the group consisting of: glaucoma, dysmenorrhoea and pre-term labour.
11 . The use of an EP 2 receptor agonist, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a condition alleviated by the inhibition of:
(i) human T-cell activation (proliferation);
(ii) the release of IL-2;
(iii) the release of TNF α ; or
(iv) the release of IFNγ.
12 . The use of an EP 2 receptor agonist, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of psoriasis.
13 . The use of an EP 2 receptor agonist, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of inflammatory lung diseases.
14 . A use according to claim 11 , wherein the EP 2 receptor agonist is a compound.
15 . A method of treating a condition which can be alleviated by the inhibtion of:
(i) human T-cell activation (proliferation);
(ii) the release of IL-2;
(iii) the release of TNF α ; or
(iv) the release of IFNγ;
which method comprises administering to a patient in need of treatment an effective amount of an EP 2 receptor agonist, or a pharmaceutically acceptable salt thereof.
16 . A method of treating a psoriasis, which method comprises administering to a patient in need of treatment an effective amount of an EP 2 receptor agonist, or a pharmaceutically acceptable salt thereof.
17 . A method of treating an inflammatory lung disease, which method comprises administering to a patient in need of treatment an effective amount of an EP 2 receptor agonist, or a pharmaceutically acceptable salt thereof.
18 . A method according to claim 15 , wherein the EP 2 receptor agonist is a compound.